Cited by 4,506Cancer-related Molecular PathwaysHeat shock proteins researchUbiquitin and proteasome pathways

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mdm2 promotes the rapid degradation of p53

Haupt, Ygal, Maya, Ruth, Kazaz, Anat, Oren, Moshe·1997·Nature

Open this paper in CoChat — free account

Abstract

The p53 tumour-suppressor protein exerts antiproliferative effects, including growth arrest and apoptosis, in response to various types of stress. The activity of p53 is abrogated by mutations that occur frequently in tumours, as well as by several viral and cellular proteins. The Mdm2 oncoprotein is a potent inhibitor of p53. Mdm2 binds the transcriptional activation domain of p53 and blocks its ability to regulate target genes and to exert antiproliferative effects. On the other hand, p53 activates the expression of the mdm2 gene in an autoregulatory feedback loop. The interval between p53 activation and consequent Mdm2 accumulation defines a time window during which p53 exerts its effects. We now report that Mdm2 also promotes the rapid degradation of p53 under conditions in which p53 is otherwise stabilized. This effect of Mdm2 requires binding of p53; moreover, a small domain of p53, encompassing the Mdm2-binding site, confers Mdm2-dependent detstabilization upon heterologous proteins. Raised amounts of Mdm2 strongly repress mutant p53 accumulation in tumour-derived cells. During recovery from DNA damage, maximal Mdm2 induction coincides with rapid p53 loss. We propose that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.

Integrity signals

Registry

Crossref · 10.1038/387296a0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,416
The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,089
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652
In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586
p53 in growth control and neoplasia
Gottlieb, T. M., & Oren, M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00019-c · Cited by 483
Self-citation

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 601–700 of 1,057

Delivery strategies and potential targets for siRNA in major cancer types
Lee, S. J., Kim, M. J., Kwon, I. C., & Roberts, T. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.010 · Cited by 146
TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
PELLER, S., & Rotter, V. (2003) · Human Mutation · doi:10.1002/humu.10190 · Cited by 141
The Emerging p53 Gene Family
Kaelin, W. G. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.594 · Cited by 143
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141
Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells
Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 141
p63 and epithelial biology
Barbieri, C. E., & Pietenpol, J. A. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.028 · Cited by 146
Rescue of mutant p53 transcription function by ellipticine
Peng, Y., Li, C., Chen, L., Sebti, S. M., & Chen, J. (2003) · Oncogene · doi:10.1038/sj.onc.1206777 · Cited by 141
The role of cell cycle regulatory proteins in the pathogenesis of melanoma
Li, W., Sanki, A., Karim, R. Z., Thompson, J. F., Lee, C. S., Zhuang, L., McCarthy, S. W., & Scolyer, R. A. (2006) · Pathology · doi:10.1080/00313020600817951 · Cited by 142
Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression
Mussman, J. G., Horn, H. F., Carroll, P. E., Okuda, M., Tarapore, P., Donehower, L. A., & Fukasawa, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203460 · Cited by 142
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein Association
Sachchidanand, Resnick‐Silverman, L., Yan, S. X., Mutjaba, S., Liu, W., Zeng, L., Manfredi, J. J., & Zhou, M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.014 · Cited by 141
Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway
Horn, H. F., & Vousden, K. H. (2008) · Oncogene · doi:10.1038/onc.2008.189 · Cited by 140
Human Immunodeficiency Virus Type 1 Nef Binds to Tumor Suppressor p53 and Protects Cells against p53-Mediated Apoptosis
Greenway, A. L., McPhee, D. A., Allen, K., Johnstone, R. W., Holloway, G., MILLS, J. S., Azad, A. A., Sankovich, S., & Lambert, P. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2692-2702.2002 · Cited by 142
Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding
Uhrı́nová, S., Uhrı́n, D., Powers, H., Watt, K., Zheleva, D. I., Fischer, P. M., McInnes, C., & Barlow, P. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.010 · Cited by 142
The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb
Juven‐Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., & Oren, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3974 · Cited by 135
Self-citation
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht
Chêne, P., Fuchs, J. P., Bohn, J. A., Garcı́a-Echeverrı́a, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 139
Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice
Shizukuda, Y., Matoba, S., Mian, O. Y., Nguyen, T., & Hwang, P. M. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-5905-8 · Cited by 139
COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas
Dornan, D., Bheddah, S., Newton, K., Ince, W., Frantz, G. D., Dowd, P., Koeppen, H., Dixit, V. M., & French, D. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2601 · Cited by 139
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
Zhang, X., Linder, S. T., & Bazzaro, M. (2020) · Cancers · doi:10.3390/cancers12040902 · Cited by 142
Molecular mechanisms of ionizing radiation‐induced apoptosis
Watters, D. J. (1999) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.1999.00824.x · Cited by 138
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138
Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus
White, E. (2001) · Oncogene · doi:10.1038/sj.onc.1204861 · Cited by 141
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity
Turenne, G. A., & Price, B. D. (2001) · BMC Cell Biology · doi:10.1186/1471-2121-2-12 · Cited by 139
p19 Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation
Radfar, A., Unnikrishnan, I., Lee, H., DePinho, R. A., & Rosenberg, N. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13194 · Cited by 140
The activation of G protein-coupled receptor 30 (GPR30) inhibits proliferation of estrogen receptor-negative breast cancer cells in vitro and in vivo
Wu, W. D., Chen, Z.-J., Zhang, K.-S., Yang, X.-L., Wu, Y.-M., Chen, X.-H., Huang, H.-B., Liu, H.-L., Cai, S.-H., Du, J., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.398 · Cited by 136
Ubiquitin–proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells
Chen, C., Sun, X., Ran, Q., Wilkinson, K. D., Murphy, T. J., Simons, J. W., & Dong, J. (2005) · Oncogene · doi:10.1038/sj.onc.1208497 · Cited by 137
Double-Stranded-RNA-Activated Protein Kinase PKR Enhances Transcriptional Activation by Tumor Suppressor p53
Cuddihy, A. R., Li, S., Tam, N. W. N., Wong, A. H., Taya, Y., Abraham, N., Bell, J. C., & Koromilas, A. E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2475 · Cited by 137
An Inhibitor of Nuclear Export Activates the p53 Response and Induces the Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated with the PODs
Laı́n, S., Midgley, C., Sparks, A., Lane, E. B., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 135
The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation
Louria‐Hayon, I., Grossman, T., Sionov, R. V., Alsheich-Bartok, O., Pandolfi, P. P., & Haupt, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301264200 · Cited by 135
Self-citation
The p53 protein family and radiation sensitivity: Yes or no?
Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 137
Inhibition of the ATM/p53 Signal Transduction Pathway by Kaposi's Sarcoma-Associated Herpesvirus Interferon Regulatory Factor 1
Shin, Y. C., Nakamura, H., Liang, X., Feng, P., Chang, H., Kowalik, T. F., & Jung, J. U. (2006) · Journal of Virology · doi:10.1128/jvi.80.5.2257-2266.2006 · Cited by 137
p73, a sophisticated p53 family member in the cancer world
Ozaki, T., & Nakagawara, A. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00116.x · Cited by 141
New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy
Bury, M., Calvé, B. L., Ferbeyre, G., Blank, V., & Lessard, F. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.01.010 · Cited by 139
MDM2 and MDMX bind and stabilize the p53-related protein p73
Ongkeko, W. M., Wang, X. Q., Siu, W. Y., Lau, A. W. S., Yamashita, K., Harris, A. L., Cox, L. S., & Poon, R. Y. C. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80367-4 · Cited by 132
Role of the Histone Acetyl Transferase Tip60 in the p53 Pathway
Legube, G., Linares, L. K., Tyteca, S., Caron, C., Scheffner, M., Chevillard, M., & Trouche, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407478200 · Cited by 136
Review: ATM: the protein encoded by the gene mutated in the radiosensitive syndrome ataxia-telangiectasia
Lavin, M. F. (1999) · International Journal of Radiation Biology · doi:10.1080/095530099139359 · Cited by 137
The p53 network in lung carcinogenesis
Robles, A. I., Linke, S. P., & Harris, C. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205563 · Cited by 138
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability
Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134
UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts
Latonen, L., Taya, Y., & Laiho, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204883 · Cited by 134
The role of ribosomal proteins in the regulation of cell proliferation, tumorigenesis, and genomic integrity
Xu, X., Xiong, X., & Sun, Y. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0018-0 · Cited by 148
Inactivation of p53 but Not p73 by Adenovirus Type 5 E1B 55-Kilodalton and E4 34-Kilodalton Oncoproteins
Roth, J. C., König, C., Wienzek‐Lischka, S., Weigel, S., Ristea, S., & Dobbelstein, M. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8510-8516.1998 · Cited by 134
The tumour suppressor RASSF1A promotes MDM2 self‐ubiquitination by disrupting the MDM2–DAXX–HAUSP complex
Song, M. S., Song, S. J., Kim, S. Y., Oh, H. J., & Lim, D. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.115 · Cited by 137
Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems
Anwar, A., Dehn, D. L., Siegel, D. M., Kepa, J. K., Tang, L. J., Pietenpol, J. A., & Ross, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211981200 · Cited by 132
TGF-β1–induced expression of human Mdm2 correlates with late-stage metastatic breast cancer
Araki, S., Eitel, J. A., Batuello, C. N., Bijangi-Vishehsaraei, K., Xie, X.-J., Danielpour, D., Pollok, K. E., Boothman, D. A., & Mayo, L. D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39194 · Cited by 133
HPV 5 and 8 E6 Abrogate ATR Activity Resulting in Increased Persistence of UVB Induced DNA Damage
Wallace, N. A., Robinson, K. L., Howie, H. L., & Galloway, D. A. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002807 · Cited by 134
Individual and combined cytotoxic effects of aflatoxin B1, zearalenone, deoxynivalenol and fumonisin B1 on BRL 3A rat liver cells
Sun, L.-H., Lei, M., Zhang, N.-Y., Gao, X., Li, C., Krumm, C. S., & Qi, D. (2014) · Toxicon · doi:10.1016/j.toxicon.2014.12.010 · Cited by 134
Induction of SOX4 by DNA damage is critical for p53 stabilization and function
Pan, X., Zhao, J., Zhang, W.-N., Li, H., Mu, R., Zhou, T., Zhang, H., Gong, W.-L., Yu, M., Man, J.-H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810147106 · Cited by 135
The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2
Uesugi, M., & Verdine, G. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14801 · Cited by 133
Ubiquitin-independent p53 proteasomal degradation
Tsvetkov, P., Reuven, N. B., & Shaul, Y. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.67 · Cited by 139
Self-Assembled Peptide–Lanthanide Nanoclusters for Safe Tumor Therapy: Overcoming and Utilizing Biological Barriers to Peptide Drug Delivery
Yan, J., He, W., Yan, S., Niu, F., Liu, T., Ma, B., Shao, Y., Yan, Y., Yang, G., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00081 · Cited by 133
Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukáš, J., Gao, D. Q., Keshmeshian, M., Wen, W., Tsao-Wei, D. D., Rosenberg, S. A., & Press, M. F. (2001) · PubMed · Cited by 133
Nucleocytoplasmic Shuttling of p53 Is Essential for MDM2-Mediated Cytoplasmic Degradation but Not Ubiquitination
O’Keefe, K. J., Li, H., & Zhang, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.18.6396-6405.2003 · Cited by 133
MDM2-dependent ubiquitination of nuclear and cytoplasmic P53
Yu, Z. K., Geyer, R. K., & Maki, C. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203980 · Cited by 133
Dual Role of p53 in Innate Antiviral Immunity
Rivas, C., Aaronson, S. A., & Muñoz‐Fontela, C. (2010) · Viruses · doi:10.3390/v2010298 · Cited by 133
C ell C ycle D ysregulation in O ral C ancer
Todd, R., Hinds, P. W., Münger, K., Rustgi, A. K., OPITZ, O. G., Suliman, Y., & Wong, D. T. (2002) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130201300106 · Cited by 132
Molecular Mechanism of Mutant p53 Stabilization: The Role of HSP70 and MDM2
Wiech, M., Olszewski, M. B., Tracz‐Gaszewska, Z., Wawrzynów, B., Żylicz, M., & Żylicz, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051426 · Cited by 132
Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer Cells
Ueki, T., Park, J.-H., Nishidate, T., Kijima, K., Hirata, K., Nakamura, Y., & Katagiri, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1809 · Cited by 133
p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice
Mizuno, S., Bogaard, H. J., Kraskauskas, D., Alhussaini, A. A., Gomez‐Arroyo, J. G., Voelkel, N. F., & Ishizaki, T. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00286.2010 · Cited by 136
The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions
Khezri, M. R., Jafari, R., Yousefi, K., & Zolbanin, N. M. (2022) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2022.104787 · Cited by 137
ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus
Ries, S., & Korn, W. M. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600006 · Cited by 132
Role of P53 and MDM2 in Treatment Response of Human Germ Cell Tumors
van der Kevie-Kersemaekers, A.-M. F., Mayer, F., Molier, M., van Weeren, P. C., Oosterhuis, J. W., Bokemeyer, C., & Looijenga, L. H. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1551 · Cited by 132
Covalent and noncovalent modifiers of the p53 protein
Jayaraman, L., & Prives, C. L. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050271 · Cited by 132
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same EndPreprint
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 131
Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair
Alt, J. R., Bouska, A., Fernandez, M. R., Cerny, R. L., Xiao, H., & Eischen, C. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413387200 · Cited by 131
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
p53: The Attractive Tumor Suppressor in the Cancer Research Field
Ozaki, T., & Nakagawara, A. (2010) · BioMed Research International · doi:10.1155/2011/603925 · Cited by 138
Molecular Basis for the Inhibition of p53 by Mdmx
Popowicz, G. M., Czarna, A., Rothweiler, U., Szwagierczak, A., Krajewski, M., Weber, L., & Holak, T. A. (2007) · Cell Cycle · doi:10.4161/cc.6.19.4740 · Cited by 131
Deregulation of the Rb and p53 Pathways in Uveal Melanoma
Brantley, M. A., & Harbour, J. W. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64817-1 · Cited by 131
Functional analysis and intracellular localization of p53 modified by SUMO-1
Kwek, S. S., Derry, J. J., Tyner, A. L., Shen, Z., & Gudkov, A. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204362 · Cited by 131
Transcriptional Repressor Activating Transcription Factor 3 Protects Human Umbilical Vein Endothelial Cells from Tumor Necrosis Factor-α-induced Apoptosis through Down-regulation ofp53 Transcription
Kawauchi, J., Zhang, C., Nobori, K., Hashimoto, Y., Adachi, M. T., Noda, A., Sunamori, M., & Kitajima, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202974200 · Cited by 131
DNA damage checkpoints and DNA replication controls in Saccharomyces cerevisiae
Foiani, M., Pellicioli, A., Lopes, M., Lucca, C., Ferrari, M., Liberi, G., Muzi-Falconi, M., & Plevani, P. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00049-x · Cited by 130
Degradation of MDM2 by the Interaction between Berberine and DAXX Leads to Potent Apoptosis in MDM2-Overexpressing Cancer Cells
Zhang, X., Gu, L., Li, J., Shah, N., He, J., Yang, L., Hu, Q., & Zhou, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1546 · Cited by 130
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans
Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129
MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension
Shen, H., Zhang, J., Wang, C., Jain, P., Xiong, M., Shi, X., Lei, Y., Chen, S., Yin, Q., Thistlethwaite, P. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048191 · Cited by 130
Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1
Laine, A., & Ronai, Z. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209924 · Cited by 133
The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation
Zilfou, J. T., Hoffman, W. H., Sank, M. J., George, D. L., & Murphy, M. E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3974-3985.2001 · Cited by 129
Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53
Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.08.027 · Cited by 128
p53 Serine 392 Phosphorylation Increases after UV through Induction of the Assembly of the CK2·hSPT16·SSRP1 Complex
Keller, D. M., & Lu, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209820200 · Cited by 127
UVB-mediated activation of p38 mitogen-activated protein kinase enhances resistance of normal human keratinocytes to apoptosis by stabilizing cytoplasmic p53
Chouinard, N., Valerie, K. C., Rouabhia, M., & Huot, J. (2002) · Biochemical Journal · doi:10.1042/bj20020072 · Cited by 128
HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53Preprint
Sasaki, T., Gan, E. C., Wakeham, A. C., Kornbluth, S. A., Mak, T. W., & Okada, H. (2007) · Genes & Development · doi:10.1101/gad.1534107 · Cited by 130
Eukaryotic DNA damage checkpoint activation in response to double-strand breaks
Finn, K., Lowndes, N. F., & Grenon, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0875-3 · Cited by 127
A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development
Post, S. M., Quintás-Cardama, A., Pant, V., Iwakuma, T., Hamir, A., Jackson, J. G., Maccio, D. R., Bond, G. L., Johnson, D. G., Levine, A. J., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.010 · Cited by 127
Pumilio 1 Suppresses Multiple Activators of p53 to Safeguard Spermatogenesis
Chen, D., Zheng, W., Lin, A., Uyhazi, K. E., Zhao, H., & Lin, H. (2012) · Current Biology · doi:10.1016/j.cub.2012.01.039 · Cited by 126
New insights into p53 activation
Brooks, C. L., & Gu, W. (2010) · Cell Research · doi:10.1038/cr.2010.53 · Cited by 102
Deubiquitinating Enzymes as Novel Anticancer Targets
Nicholson, B., Marblestone, J. G., Butt, T. R., & Mattern, M. R. (2007) · Future Oncology · doi:10.2217/14796694.3.2.191 · Cited by 128
PML interaction with p53 and its role in apoptosis and replicative senescence
Pearson, M. A., & Pelicci, P. G. (2001) · Oncogene · doi:10.1038/sj.onc.1204856 · Cited by 126
Control of cell migration: a tumour suppressor function for p53?
Roger, L., Gadéa, G., & Roux, P. (2006) · Biology of the Cell · doi:10.1042/bc20050058 · Cited by 132
Classic and novel roles of p53: prospects for anticancer therapy
Fuster, J. J., Sanz-Gonzalez, S. M., Moll, U. M., & Andrés, V. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.03.002 · Cited by 128
Cocompartmentalization of p53 and Mdm2 Is a Major Determinant for Mdm2-Mediated Degradation of p53
Xirodimas, D. P., Stephen, C. W., & Lane, D. P. (2001) · Experimental Cell Research · doi:10.1006/excr.2001.5314 · Cited by 127
Into the heart: The emerging role of the ubiquitin–proteasome system
Willis, M. S., & Patterson, C. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.07.015 · Cited by 125
From structure to dynamics: Frequency tuning in the p53–Mdm2 network
Abou-Jaoudé, W., Ouattara, D. A., & Kaufman, M. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.02.005 · Cited by 124
Apoptosis-modulating agents in combination with radiotherapy—current status and outlook
Belka, C., Jendrossek, V., Pruschy, M. N., Vink, S. R., Verheij, M., & Budach, W. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.067 · Cited by 127
5′-3′-UTR interactions regulate p53 mRNA translation and provide a target for modulating p53 induction after DNA damage
Chen, J., & Kastan, M. B. (2010) · Genes & Development · doi:10.1101/gad.1968910 · Cited by 127
MDM2 and MDMX: Alone and together in regulation of p53.
Shadfan, M., Lopez-Pajares, V., & Yuan, Z.-M. (2012) · PubMed · Cited by 125
Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2
Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 125
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 127
MDM2-arbiter of p53's destruction
Lane, D. P., & Hall, P. A. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01119-5 · Cited by 126
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124

Authors: Haupt, Y., Maya, R., Kazaz, A., & Oren, M.
Affiliations: Hebrew University of Jerusalem (IL)
Weizmann Institute of Science (IL)
ORCID: Haupt, Ygal
Maya, Ruth
Oren, Moshe
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1997-05
Volume: 387
Issue: 6630
Pages: 296-299
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/387296a0
OpenAlex: W2082979850
Cited by: 4,506
References: 29
Citations by year: 2026: 114 · 2025: 117 · 2024: 136 · 2023: 150 · 2022: 163 · 2021: 167 · 2020: 172 · 2019: 131 · 2018: 128 · 2017: 139 · 2016: 138 · 2015: 122 · 2014: 188 · 2013: 147 · 2012: 197
FWCI: 78.92
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords: MDM2, p53, p53 degradation, protein stabilization, p53-MDM2 interaction, DNA damage response, tumour suppressor, autoregulatory loop, mutant p53
MeSH terms: Animals, HeLa Cells, Humans, Nuclear Proteins, Protein Binding, Proto-Oncogene Proteins, Recombinant Fusion Proteins, RNA, Messenger, Transfection, Tumor Cells, Cultured, Down-Regulation, Tumor Suppressor Protein p53, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mdm2 promotes the rapid degradation of p53

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks